ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,636.00
-15.00 (-0.91%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -15.00 -0.91% 1,636.00 1,638.00 1,639.00 1,661.50 1,635.50 1,656.50 4,329,161 16:35:12
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.69 67.46B

GlaxoSmithKline PLC Director/PDMR Shareholding (2241V)

05/08/2015 3:41pm

UK Regulatory


Gsk (LSE:GSK)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Gsk Charts.

TIDMGSK

RNS Number : 2241V

GlaxoSmithKline PLC

05 August 2015

GlaxoSmithKline plc

Notification of Transactions of Directors and Persons Discharging Managerial Responsibility

Grant of Conditional Share Award under GlaxoSmithKline Performance Share Plan

I give below details of changes in the interests of the below-mentioned Person Discharging Managerial Responsibility ("PDMR") in the Ordinary Shares of the Company ("Ordinary Shares") as a result of an award made under the 2009 Performance Share Plan ("PSP") on 4 August, 2015.

This award was made following the completion and implementation of the three-way transaction with Novartis in recognition of Ms Walmsley's increased role and responsibility as CEO of the new joint venture, GSK Consumer Healthcare.

 
 PDMR             Number of Ordinary Shares subject 
                             to the award 
---------------  ---------------------------------- 
 Emma Walmsley                 59,493 
---------------  ---------------------------------- 
 

The PSP was approved by shareholders on 20 May 2009, and allows a performance-related opportunity in the form of conditional awards to be made to senior executives in the Group, including the Executive Directors.

Under the terms of the PSP, a conditional award is granted over a specific number of Ordinary Shares, and the percentage of the award that ultimately vests is dependent on the level of achievement against performance targets set by the Remuneration Committee. This award is conditional on three equally weighted performance measures, as set out in announcements from the Company on 12 February and 31 July 2015.

Dividends will accrue on the conditional award of Ordinary Shares during the three-year performance period, but will only vest to the extent that the awards themselves vest at the end of the performance period.

The vesting date for this conditional award will be the date, following the end of the three year performance period, on which the Remuneration Committee determines the extent to which the performance conditions have been achieved or such other later date as determined by the Remuneration Committee.

The above conditional award was made on 4 August 2015. The closing price of an Ordinary Share on 4 August 2015 was GBP14.01.

The Company and Ms Walmsley were advised of this transaction on 5 August 2015.

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

5 August 2015

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSZELFBEVFXBBV

1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock